Rapastinel alleviates the neurotoxic effect induced by NMDA receptor blockade in the early postnatal mouse brain
| Autor: | Peter Gass, Natascha Pfeiffer, Dragos Inta, Undine E. Lang, Andrei-Nicolae Vasilescu, Anne S. Mallien |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Agonist
business.industry medicine.drug_class Antagonist Neurotoxicity General Medicine Pharmacology medicine.disease Neuroprotection 030227 psychiatry 03 medical and health sciences Psychiatry and Mental health Glutamatergic 0302 clinical medicine Rapastinel Medicine NMDA receptor Antidepressant Pharmacology (medical) business 030217 neurology & neurosurgery Biological Psychiatry |
| Zdroj: | European Archives of Psychiatry and Clinical Neuroscience. 271:1587-1591 |
| ISSN: | 1433-8491 0940-1334 |
| DOI: | 10.1007/s00406-020-01180-5 |
| Popis: | Rapastinel is a novel psychoactive substance that acts as an N-methyl-D-aspartate-receptor (NMDAR) agonist and triggers antidepressant- and antipsychotic-like effects in animal models. However, it is unknown if rapastinel possesses a better side-effect profile than fast-acting glutamatergic antidepressants, like ketamine, which trigger neurotoxicity in the perinatal rodent cortex and protracted schizophrenia-like alterations. Here we found a remarkable neuroprotective effect of rapastinel against apoptosis induced by the NMDAR antagonist MK-801 in comparison to that elicited by clozapine and the mGlu2/3 agonist LY354740. These results suggest the potential therapeutic/prophylactic effect of rapastinel in ameliorating deleterious effects induced by NMDAR blockade during neurodevelopment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink